Skip to main content

Chemotherapy and Related Drugs for Neuroblastoma

Chemotherapy (chemo) is the use of anti-cancer drugs, which may be given into a vein or by mouth. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it cannot be removed completely with surgery.

When might chemotherapy be used?

Whether a child with neuroblastoma will get chemotherapy depends on their risk group, which is based on the stage (extent) and location of the cancer, the child’s age, and other factors.

Some children with neuroblastoma are treated with chemo before surgery (neoadjuvant chemotherapy) or after surgery (adjuvant chemotherapy).

In other cases, especially when the cancer has spread too far to be removed completely by surgery, chemo is the main treatment.

Which chemo drugs are used for neuroblastoma?

Chemo for neuroblastoma usually includes a combination of drugs. If chemo is needed, the types of drugs and length of treatment depend on a child’s risk group. The main chemo drugs used for newly diagnosed neuroblastoma include:

  • Cyclophosphamide
  • Cisplatin or carboplatin
  • Vincristine
  • Doxorubicin (Adriamycin)
  • Etoposide
  • Topotecan
  • Melphalan (sometimes used during stem cell transplant)
  • Busulfan (sometimes used during stem cell transplant)
  • Thiotepa (sometimes used during stem cell transplant)

The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine and etoposide, but others may be used.

For children in the high-risk group, other drugs might be added as well, and some drugs might be given at higher doses. This may be followed by a stem cell transplant.

As researchers learn more about the genes that cause neuroblastoma, targeted therapies may be recommended as part of the treatment plan.

Doctors give chemo in cycles. Treatment is given for a few days in a row, followed by time off to allow the body time to recover. The cycles are typically repeated every 3 or 4 weeks. The total length of treatment depends on which risk group the child is in—higher risk groups usually require longer treatment.

Possible side effects of chemotherapy

Chemo drugs affect cells that grow fast. While cancer cells grow fast, other healthy cells in the body do too—for example blood-forming cells, hair cells, and cells that make up the lining of our gut. Damage caused by these drugs to fast-growing healthy cells results in side effects. The side effects of chemo depend on the type and dose of drugs given and the length of time they are taken.

General side effects of chemo

Side effects common to many chemo drugs include:

  • Hair loss
  • Mouth sores
  • Loss of appetite
  • Nausea and vomiting
  • Diarrhea or constipation

Chemo can damage the bone marrow, where new blood cells are made. This can lead to low blood cell counts, which can result in:

  • Increased chance of infections (from having too few white blood cells)
  • Easy bruising or bleeding (from having too few blood platelets)
  • Fatigue (from having too few red blood cells)

Most of these side effects tend to go away after treatment is finished. There are often ways to lessen these side effects. For example, drugs can be given to help prevent or reduce nausea and vomiting. Be sure to let your child’s doctor or nurse know if your child has side effects so they can be managed.

Long-term side effects of chemo

Chemotherapy can also have some longer-term side effects. For example, some drugs can increase the risk of later developing another type of cancer (such as leukemia). While this is a serious risk, it is not common, and the small increase in risk must be weighed against the importance of chemotherapy in treating neuroblastoma. For more on the possible long-term effects of treatment, see After Neuroblastoma Treatment.

Side effects of certain chemo drugs

Some chemo drugs can also have specific side effects. For example:

Cyclophosphamide can damage the bladder, which can cause blood in the urine. The risk of this can be lowered by giving the drug with plenty of fluids and with a drug called mesna, which helps protect the bladder. This drug can also damage the ovaries or testicles, which could affect fertility (the ability to have children). Talk to your child’s doctor about whether this is a concern. There may be options to help preserve their fertility.

Doxorubicin can damage the heart. Doctors try to reduce this risk as much as possible by limiting the doses of doxorubicin, checking the heart with an echocardiogram (an ultrasound of the heart), and giving medicine to protect the heart (such as dexrazoxane) during treatment. Doxorubicin can also cause skin damage if it leaks out of the vein while it is being given.

Cisplatin and carboplatin can affect the kidneys. Giving plenty of fluids can help reduce this risk. These drugs can also affect hearing. Your child’s doctor may order hearing tests (audiograms) during or after treatment.

Vincristine can cause nerve damage (neuropathy). Some patients may have tingling, numbness, weakness, or pain, particularly in the hands and feet. For example, some children develop a condition called foot drop, which can make it difficult to lift the front part of the foot. This may make it hard to walk, but therapy and braces can help. Most of the time symptoms get better when treatment ends, but they may not go away completely.

The doctors and nurses will watch closely for side effects. Do not hesitate to ask the cancer care team any questions about side effects.

For more information on the possible late or long-term side effects of chemo, including infertility and second cancers, see Late and Long-term Effects of Childhood Cancer Treatment.

Ornithine decarboxylase inhibitor

Eflornithine (also known as DFMO or Iwilfin) works in a different way than standard chemotherapy drugs. This drug blocks an enzyme inside cells known as ornithine decarboxylase (ODC), which is important for cell growth.

If the cancer has already shrunk in response to previous treatment that included an anti-GD2 antibody, DFMO can be used in children with high-risk neuroblastoma to lower the risk of it coming back.

This drug is taken as pills, typically twice a day for up to 2 years, if tolerated.

Side effects of DFMO

Common side effects of this drug include:

  • Infections, including ear, sinus, skin, respiratory, and urinary tract infections (UTIs)
  • Red and swollen eyes (pink eye)
  • Diarrhea
  • Vomiting
  • Cough
  • Stuffy, runny, or itchy nose, or sneezing
  • Fever

More serious side effects can include:

This drug can damage the bone marrow, where new blood cells are made. This can lead to:

  • Increased chance of infections (from having too few white blood cells)
  • Easy bruising or bleeding (from having too few blood platelets)
  • Feeling tired (from having too few red blood cells)

Tests will be done to check blood counts before and during treatment.

This drug can damage the liver, which might result in jaundice (yellowing of the eyes and skin), easy bruising or bleeding, nausea, and other problems. Blood tests will be done to check liver function before and during treatment.

This drug might cause hearing loss, which can sometimes be serious. For people getting this drug, hearing will be checked before and during treatment.

More information about chemotherapy

For more general information about how chemotherapy is used to treat cancer, see Chemotherapy.

To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.

side by side logos for American Cancer Society and American Society of Clinical Oncology

Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).

 

Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and long-term heart function in survivors of childhood cancer. J Clin Oncol. 2023;41(12):2248-2257. doi:10.1200/jco.22.02423

Dome JS, Rodriguez-Galindo C, Spunt SL, Santana VM. Chapter 92: Pediatric solid tumors. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, PA. Elsevier; 2020.

National Cancer Institute. Neuroblastoma Treatment (PDQ). 2024. Accessed at https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq on March 24, 2025.

Park JR, Hogarty MD, Bagatell R, et al. Chapter 23: Neuroblastoma. In: Blaney SM, Adamson PC, Helman LJ, eds. Pizzo and Poplack’s Principles and Practice of Pediatric Oncology. 8th ed. Philadelphia Pa: Lippincott Williams & Wilkins; 2021.

Shohet JM, Nuchtern JG, Foster JH. Treatment and prognosis of neuroblastoma. UpToDate. 2025. Accessed at https://www.uptodate.com/contents/treatment-and-prognosis-of-neuroblastoma on March 24, 2025.

 

Last Revised: June 26, 2025

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.